Practice Update: Diabetes

CONTENTS 3

RESEARCH Editor’s picks 4 Improved Diet Quality Associated with Reduced Mortality 5 Canagliflozin May Reduce Cardiovascular Events in Type 2 Diabetes 6 Glycemic Control Reduces Risk of Coronary Events in Men With Type 1 Diabetes 7 Higher Two-Hour Post- Load Glucose Predicts Risk for Cardiovascular Events in CAD Microvascular complications 15 Effects Of Empagliflozin on the Urinary Albumin-to- Creatinine Ratio in Patients with Type 2 Diabetes and Established CVD

Conference coverage 8 American Diabetes Association Scientific Sessions 2017 8 The PCSK9 Inhibitor in Insulin-Dependent Patients with Type 2 Diabetes 9 SGLT2 Inhibitors are Cover 4 Improved Diet Quality Associated with Reduced Mortality

PracticeUpdate is guided by a world-renowned Editorial and Advisory Board that represents community practitioners and academic specialists with cross-disciplinary expertise.

Silvio Inzucchi MD Richard Pratley MD, Deborah Wexler MD

Editor-in-Chief

Associate Editors

Editorial Contributors Lisa Parikh,

Ana Perdigoto MDPhD, Camille Powe MD

PracticeUpdate® is a registered trademark of Elsevier Inc. © 2017 Elsevier Inc. All rights reserved. ABOUT PracticeUpdate Diabetes provides coverage of key research from leading international conferences, and a collection of top journal articles and accompanying expert commentaries in a convenient print periodical. These and more are also available online at www. practiceupdate.com PracticeUpdate and PracticeUpdate Diabetes are commercially supported by advertising, sponsorship, and educational grants. Individual access to PracticeUpdate.com is free. Premium content is available to any user who registers with the site. While PracticeUpdate is a commercially-sponsored product, it maintains the highest level of academic rigour, objectivity, and fair balance associated with all Elsevier products. No editorial content is influenced in any way by commercial sponsors or content contributors. DISCLAIMER PracticeUpdate Diabetes has been developed for specialist medical professionals. The ideas and opinions expressed in this publication do not necessarily reflect those of the Publisher. Elsevier will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Please consult the full current Product Information before prescribing any medication mentioned in this publication. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. SALES Fleur Gill fleur.gill@elsevier.com Linnea Mitchell-Taverner l.mitchell@elsevier.com PRODUCTION Editorial Manager Anne Neilson anne.neilson@elsevier.com Editorial Project Manager Carolyn Ng Designer Jana Sokolovskaja

11 The PCSK9 Inhibitor Alirocumab Reduces Non-HDL Cholesterol in Patients with Type 2 Diabetes and Mixed Dyslipidaemia 12 Autoantigen GAD Vaccine is Safe for Children at High Risk of Type 1 Diabetes 13 New, Ultra-Long- Acting Insulin Degludec Demonstrates Cardiovascular Safety and Reduces Risk of Severe Hypoglycemia 14 Long-Term Metformin

Alirocumab Reduces LDL and Non-HDL Cholesterol

Associated with Reduced Cardiovascular Disease in Patients with Type 2 Diabetes Systems Prove Safe and Effective in Controlling Glucose Levels in Children and Adults with Type 2 Diabetes

10 Hybrid Closed-Loop

Diabetes 16 High Prevalence of Diabetic Peripheral Neuropathy Found in Young People with Diabetes 17 Glucose Self-Monitoring in Non-Insulin Treated Patients with Type 2 Diabetes Does Not Improve Glycemic Control

Treatment Found to Reduce Risk of Heart Disease in Adults with Type 1 Diabetes

Features 21 Dr Peter Libby on New Territory in Targeting Triglycerides 22 My Approach to the Elderly Patient with Resistant Hypertension

Cardiovascular complications 18 Differential Effects

of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function

19 With Aspirin and Statin Use, Diabetics Without CAD Have Same Risk for MI as Non-Diabetics Obesity 20 Physical Activity Alters Genetic Susceptibility to Long-Term Weight Gain

PracticeUpdate Diabetes is published by Elsevier Australia ISSN 2208-1488 (Print) ISSN 2208-1496 (Online)

ABN 70 001 002 357 475 Victoria Avenue Chatswood NSW 2067 Australia Locked Bag 7500 Chatswood DC NSW 2067 EMED081701

VOL. 1 • NO. 2 • 2017